Johnson & Johnson stock heads into the open after a 0.29 percent dip

Johnson & Johnson stock closed at USD 265.58 on the New York Stock Exchange on September 11, 2026, down 0.29 percent for the session per NYSE data cited by StockAnalysis. The shares ended the day slightly below their recent level near USD 266, while the broader U.S. equity market faced rate-hike worries linked to firm inflation readings.

September 11, 2026 in numbers

Johnson & Johnson Inc. (ISIN US4781601046, NYSE: JNJ) finished trading on September 11, 2026 at USD 265.58, with a 0.29 percent decline from the prior close, and later showed an after-hours indication of USD 265.99 in USD according to quote data on StockAnalysis. Intraday, the stock oscillated around the mid-260s level and sat close to its 12-month high, with recent filings noting that JNJ opened Friday's session at about USD 265.91. MarketBeat described shares as trading near their 12-month high around USD 265.91, underscoring that the latest close left Johnson & Johnson only a modest distance from that reference zone.MarketBeat In the same session, U.S. stock index futures and major benchmarks were described as recovering from a weak week as cooling oil prices offered some relief, though strong inflation data continued to cement expectations for further rate hikes.The Economic Times

Dividend metrics also framed the valuation backdrop. StockAnalysis reported an annual dividend of USD 5.36 per share for Johnson & Johnson, translating into a dividend yield of about 2.02 percent at the September 11, 2026 closing price of USD 265.58, which helps explain the income profile at this level.StockAnalysis In separate commentary on recent trading, MarketBeat noted that the stock was near its 12-month high while institutional investors adjusted their positions, providing a context of steady demand despite the small pullback on the day.MarketBeat

Today’s focus on deal talks and macro signals

Today, attention around Johnson & Johnson is shaped in part by ongoing reports that Apollo Global Management is in talks to acquire the company’s orthopedics unit, a transaction that could reach around USD 20 billion and reshape parts of its medical devices portfolio.Reuters A Bloomberg-based brief compiled by Global Advisors highlighted that Johnson & Johnson shares edged higher after the close on Friday as investors digested this late report, indicating that deal speculation is an important narrative heading into the U.S. open.Global Advisors Alongside company-specific deal news, traders are watching the broader macro backdrop, as liveblogs from The Economic Times point to strong inflation data that reinforced expectations for tighter monetary policy, a factor that can influence large healthcare names like Johnson & Johnson through its impact on discount rates and defensive-sector flows.The Economic Times No specific earnings release or ex-dividend date for Johnson & Johnson is scheduled for today in the referenced materials, so investors are likely to concentrate on the evolution of the potential orthopedics deal and incoming macro data as key factors into today's session.